Research programme: somatropin mimetics - Celera Genomics/Pfizer

Drug Profile

Research programme: somatropin mimetics - Celera Genomics/Pfizer

Alternative Names: Growth hormone mimetics research programme - Celera Genomics/Pfizer; Somatropin mimetics research programme - Celera Genomics/Pfizer

Latest Information Update: 19 Jan 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celera Genomics Group; Pfizer
  • Class
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Growth disorders

Most Recent Events

  • 19 Jan 2005 No development reported - Preclinical for Growth disorders in USA (unspecified route)
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 04 Dec 2001 Axys Pharmaceuticals has been acquired by Celera Genomics Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top